Clinical characteristics of Egyptian male patients with COVID‐19 acute respiratory distress syndrome

Doghish, Ahmed S.; Elkhatib, Walid F.; Hassan, Essam A.; Elkhateeb, Ahmed F.; Mahmoud, Eman; Ahmed, Mona; Khalil, Mahmoud A F

doi:10.1371/journal.pone.0249346

Cited by 64 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that fever, fatigue, and cough were the predominant symptoms, while sore throat, loss of taste, anosmia, and GIT symptoms were reported but with less frequency. These observations are in line with the findings of previous investigations (Doghish et al, 2021;Ibrahim et al, 2021;Alotaibi et al, 2022b;Cascella et al, 2022).…”

Section: Discussionsupporting

confidence: 94%

“…The clade 20A with the S_D614G mutation was reported in 17 samples. Our findings regarding the prevalence of different clades during the third wave of the COVID-19 pandemic are consistent with previous studies conducted in Egypt and worldwide ( Davies et al, 2021 ; Doghish et al, 2021 ; Gravagnuolo et al, 2021 ; Alotaibi et al, 2022a ; Hart et al, 2022 ; Lambrou et al, 2022 ; Seadawy et al, 2022 ).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021

Seadawy¹,

Binsuwaidan

Alotaibi

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

In December 2019, a mysterious viral pneumonia first developed in Wuhan, China, resulting in a huge number of fatal cases. This pneumonia, which was named COVID-19, was attributed to a novel coronavirus, SARS-CoV-2. The emerging SARS-CoV-2 mutations pose the greatest risk to human health because they could result in an increase in the COVID-19 severity or the failure of current vaccines. One of these notable mutations is the SARS-CoV-2 Delta variant (B.1.617) that was first detected in India and has rapidly expanded to 115 countries worldwide. Consequently, in this study, we performed next-generation sequencing and phylogenetic analysis of SARS-CoV-2 during the third wave of the pandemic to determine the SARS-CoV-2 variants of concern (VOC) prevalence in Egypt. We observed several mutational patterns, revealing that SARS-CoV-2 evolution has expanded in Egypt with a considerable increase in the number of VOC. Therefore, the Egyptian authorities should take an appropriate approach to investigate the compatibility of already employed vaccines with this VOC and to examine the efficacy of the existing therapeutic regimen against new SARS-CoV-2 variants.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 92%

The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021

Seadawy¹,

Binsuwaidan

Alotaibi

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“… 9 This reduction has also been shown to be associated with poor outcomes. 10 , 11 In addition, hyperinflammation seems to contribute to COVID‐19‐related coagulopathy, and microthrombosis was reported to occur in almost every system, including the musculoskeletal system. 12 Not only lower lymphocyte levels but also elevated levels of d ‐dimer are related to poor outcomes 13 and this elevation may be related to this coagulopathy in those of our patients whose musculoskeletal symptoms began with or were aggravated by COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

Musculoskeletal symptoms and related factors in postacute COVID‐19 patients

et al. 2021

View full text Add to dashboard Cite

Aim There is a lack of an overview of the factors associated with postacute COVID‐19 musculoskeletal symptoms. The aims of this study were as follows: 1‐ to evaluate the most frequent admission symptoms and the frequency of musculoskeletal symptoms in postacute COVID‐19 patients; and 2‐ to determine the related factors with the postacute COVID‐19 musculoskeletal symptoms. Methods A total of 280 postacute COVID‐19 patients (183 females, 97 males) were enrolled and divided into two groups: 1‐ patients whose musculoskeletal symptoms initiated with or were aggravated by COVID‐19 (n = 240); and 2‐ patients whose musculoskeletal symptoms did not change with COVID‐19 (n = 40). The variables were demographic and treatment data, symptoms on admission, postacute COVID‐19 symptoms, laboratory results (complete blood count, erythrocyte sedimentation rate, C‐reactive protein, ferritin and d ‐dimer), chest computed tomography findings and symptoms during acute COVID‐19. Results Most of the patients have fatigue (71.8%), spine pain (70.7%) and myalgia (60.7%). The most common pain region was the back (30.4%). The frequency of dyspnoea was 30%, cough 18.5% and chest pain 10.7%. Having any chronic disease ( P = .031), the duration of hospital stay ( P = .016), frequency of back pain during acute COVID‐19 ( P = .018), tomography findings and d ‐dimer ( P = .035) levels were significantly higher, and lymphocyte ( P = .024) levels were significantly lower in the patients whose symptoms began with or were aggravated by COVID‐19. Conclusion Back pain was the most frequent symptom on admission. The most common postacute COVID‐19 musculoskeletal symptoms were fatigue, spine pain and myalgia. Lower lymphocyte and higher d ‐dimer levels, the presence of COVID‐19 findings in tomography and back pain during acute COVID‐19 infection, higher duration of hospital stay and having chronic diseases were related to post‐COVID‐19 musculoskeletal symptoms.

show abstract

“…Studies of CRP levels in association with COVID-19 in Africa appear to be rare, but the metabolic marker may not be rare. Some reports indicated that CRP levels were associated with adverse outcomes in patients [ 89 – 91 ]. In general, CRP levels are high in many African countries or in African Americans, especially in association with diabetes, hypertension, or infectious diseases [ 92 ].…”

Section: The African Continent and Sars-cov-2mentioning

confidence: 99%

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic: Are Africa’s Prevalence and Mortality Rates Relatively Low?

Mariam

2022

Advances in Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease 19 (COVID-19), has been rapidly spreading since December 2019, and within a few months, it turned out to be a global pandemic. The disease affects primarily the lungs, but its pathogenesis spreads to other organs as well. However, its mortality rates vary, and in the majority of infected people, there are no serious consequences. Many factors including advanced age, preexisting health conditions, and genetic predispositions are believed to exacerbate outcomes of COVID-19. The virus contains several structural proteins including the spike (S) protein with subunits for binding, fusion, and internalization into host cells following interaction with host cell receptors and proteases (ACE2 and TMPRSS2, respectively) to cause the subsequent pathology. Although the pandemic has spread into all countries, most of Africa is thought of as having relatively less prevalence and mortality. Several hypotheses have been forwarded as reasons for this and include warmer weather conditions, vaccination with BCG (i.e., trained immunity), and previous malaria infection. From genetics or metabolic points of view, it has been proposed that most African populations could be protected to some degree because they lack some genetic susceptibility risk factors or have low-level expression of allelic variants, such as ACE2 and TMPRSS2 that are thought to be involved in increased infection risk or disease severity. The frequency of occurrence of α-1 antitrypsin (an inhibitor of a tissue-degrading protease, thereby protecting target host tissues including the lung) deficiency is also reported to be low in most African populations. More recently, infections in Africa appear to be on the rise. In general, there are few studies on the epidemiology and pathogenesis of the disease in African contexts, and the overall costs and human life losses due to the pandemic in Africa will be determined by all factors and conditions interacting in complex ways.

show abstract

Clinical characteristics of Egyptian male patients with COVID‐19 acute respiratory distress syndrome

Cited by 64 publications

References 25 publications

The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021

The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021

Musculoskeletal symptoms and related factors in postacute COVID‐19 patients

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic: Are Africa’s Prevalence and Mortality Rates Relatively Low?

Contact Info

Product

Resources

About